690998-35-7

Basic information

• Product Name: 6-(4-fluoro-3-methyl-benzylcarbamoyl)-pyrimidine-4-carboxylic acid
• Synonyms: 6-(4-fluoro-3-methyl-benzylcarbamoyl)-pyrimidine-4-carboxylic acid
• CAS NO: 690998-35-7
• Molecular Weight: 289.266
• Mol File: 690998-35-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 6-(4-fluoro-3-methyl-benzylcarbamoyl)-pyrimidine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-fluoro-3-methyl-benzylcarbamoyl)-pyrimidine-4-carboxylic acid(690998-35-7)
• EPA Substance Registry System: 6-(4-fluoro-3-methyl-benzylcarbamoyl)-pyrimidine-4-carboxylic acid(690998-35-7)

Safety Data

• Hazardous Substances Data: 690998-35-7(Hazardous Substances Data)

Upstream product

• 612088-38-7 pyrimidine-4,6-dicarboxylic acid monomethyl ester 
• 185147-08-4 4-fluoro-3-methylbenzonitrile 
• 16490-02-1 pyrimidine-4,6-dicarboxylic acid 
• 1558-17-4 4,6-dimethylpyrimidine 
• 6345-43-3 pyrimidine-4,6-dicarboxylic acid dimethyl ester 

Downstream Products

• 1605324-97-7 pyrimidine-4,6-dicarboxylic acid 4-{[dideutero-(4-formyl-phenyl)-methyl]-amide} 6-(4-fluoro-3-methyl-benzylamide) 
• 1605324-87-5 4-({[6-(4-fluoro-3-methyl-benzylcarbamoyl)-pyrimidine-4-carbonyl]-amino }-methyl)-benzoic acid methyl ester 

Relevant articles and documents

Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis

Osteoarthritis (OA) is a chronic disorder that causes damage to the cartilage and surrounding tissues and is characterized by pain, stiffness, and loss of function. Current treatments for OA primarily involve providing only relief of symptoms but does not

MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES

The present invention relates generally to bis-amide containing MMP inhibiting compounds, and more particularly to selectively deuterated bis-amide MMP-13 inhibiting compounds that exhibit increased stability or potency in relation to currently known MMP-

Multicyclic bis-amide MMP inhibitors

The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.